Aquinox Pulls In $18M In Venture Funds As COPD Drug Moves Forward
This article was originally published in The Pink Sheet Daily
The Canadian company will use the funds from its Series C financing to advance its lead drug candidate through Phase II testing in two indications, including COPD.
You may also be interested in...
FDA is facing several novel candidates for chronic obstructive pulmonary disease in 2013; those products should expect close scrutiny due to past issues with class safety and new signals in clinical trials.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.